Teva up on M&A deal; Elan, Biogen slide
March 18, 2010 at 09:59 AM EDT
Teva Pharmaceutical Industries was the lead advancer among the large-cap drug stocks early Thursday, gaining on news that it plans to buy German generic drug-maker Ratiopharm Group International for $5 billion.
